These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 31120856)

  • 41. Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening.
    Assel M; Dahlin A; Ulmert D; Bergh A; Stattin P; Lilja H; Vickers AJ
    Eur Urol; 2018 Jun; 73(6):961-967. PubMed ID: 29066048
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Aging Mountaineer: PSA screening in older men--of value or should we skip this test?
    Crigger C; Salkini M; Zaslau S
    W V Med J; 2016; 112(3):36-40. PubMed ID: 27301153
    [TBL] [Abstract][Full Text] [Related]  

  • 43. What Have Patients Been Hearing From Providers Since the 2012 USPSTF Recommendation Against Routine Prostate Cancer Screening?
    Haider MR; Qureshi ZP; Horner R; Friedman DB; Bennett C
    Clin Genitourin Cancer; 2017 Dec; 15(6):e977-e985. PubMed ID: 28625690
    [TBL] [Abstract][Full Text] [Related]  

  • 44. On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer.
    Bangma CH; van Schaik RH; Blijenberg BG; Roobol MJ; Lilja H; Stenman UH
    Eur J Cancer; 2010 Nov; 46(17):3109-19. PubMed ID: 21047594
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prostate cancer: screening and early detection.
    Cookson MM
    Cancer Control; 2001; 8(2):133-40. PubMed ID: 11326167
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Estimating the harms and benefits of prostate cancer screening as used in common practice versus recommended good practice: A microsimulation screening analysis.
    Carlsson SV; de Carvalho TM; Roobol MJ; Hugosson J; Auvinen A; Kwiatkowski M; Villers A; Zappa M; Nelen V; Páez A; Eastham JA; Lilja H; de Koning HJ; Vickers AJ; Heijnsdijk EA
    Cancer; 2016 Nov; 122(21):3386-3393. PubMed ID: 27459245
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prostate-specific antigen-based screening: controversy and guidelines.
    Kim EH; Andriole GL
    BMC Med; 2015 Mar; 13():61. PubMed ID: 25857320
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pathology consultation on prostate-specific antigen testing.
    Noguez JH; Fantz CR
    Am J Clin Pathol; 2014 Jul; 142(1):7-15. PubMed ID: 24926079
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Risks of PSA screening now better understood.
    Peres J
    J Natl Cancer Inst; 2013 Nov; 105(21):1590-2. PubMed ID: 24142893
    [No Abstract]   [Full Text] [Related]  

  • 50. Prostate-specific antigen utilization in Ontario: extent of testing in patients with and without cancer.
    Bunting PS; Chong N; Holowaty EJ; Goel V
    Clin Biochem; 1998 Aug; 31(6):501-11. PubMed ID: 9740973
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial.
    Martin RM; Donovan JL; Turner EL; Metcalfe C; Young GJ; Walsh EI; Lane JA; Noble S; Oliver SE; Evans S; Sterne JAC; Holding P; Ben-Shlomo Y; Brindle P; Williams NJ; Hill EM; Ng SY; Toole J; Tazewell MK; Hughes LJ; Davies CF; Thorn JC; Down E; Davey Smith G; Neal DE; Hamdy FC;
    JAMA; 2018 Mar; 319(9):883-895. PubMed ID: 29509864
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of an Educational Program for Prostate Cancer Prevention on knowledge and PSA Testing in Men Over 50 Years old in Community Areas of Shiraz in 2016.
    Molazem Z; Ebadi M; Khademian M; Zare R
    Asian Pac J Cancer Prev; 2018 Mar; 19(3):633-637. PubMed ID: 29580031
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prostate cancer screening: clinical impact of WHO calibration of Beckman Coulter Access prostate-specific antigen assays.
    Fillée C; Tombal B; Philippe M
    Clin Chem Lab Med; 2010 Feb; 48(2):285-8. PubMed ID: 20001849
    [TBL] [Abstract][Full Text] [Related]  

  • 54. PSA screening for prostate cancer.
    Sadi MV
    Rev Assoc Med Bras (1992); 2017 Aug; 63(8):722-725. PubMed ID: 28977112
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Testing and referral patterns in the years surrounding the US Preventive Services Task Force recommendation against prostate-specific antigen screening.
    Hutchinson R; Akhtar A; Haridas J; Bhat D; Roehrborn C; Lotan Y
    Cancer; 2016 Dec; 122(24):3785-3793. PubMed ID: 27658175
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians.
    Qaseem A; Barry MJ; Denberg TD; Owens DK; Shekelle P;
    Ann Intern Med; 2013 May; 158(10):761-769. PubMed ID: 23567643
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prostate cancer screening.
    Sikaris K
    Pathology; 2012 Feb; 44(2):99-109. PubMed ID: 22198258
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prostate-specific antigen: an evolving role in diagnosis, monitoring, and treatment evaluation in prostate cancer.
    Payne H; Cornford P
    Urol Oncol; 2011; 29(6):593-601. PubMed ID: 20060331
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Indirect consequences of PSA testing for prostate cancer screening].
    Naïmi R; Senglet M; De Gorski A; Kherad O
    Rev Med Suisse; 2020 Feb; 16(680):275-277. PubMed ID: 32022494
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Contemporary National Trends of Prostate Cancer Screening Among Privately Insured Men in the United States.
    Kim SP; Karnes RJ; Gross CP; Meropol NJ; Van Houten H; Abouassaly R; Shah ND
    Urology; 2016 Nov; 97():111-117. PubMed ID: 27527411
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.